Introduction
Type 2 diabetes (T2D) increases the risk for the development of heart failure (HF) by two-to five-fold, 1 independent of other HF risk factors. Patients with the combination of HF and T2D are at particularly high risk of adverse outcomes, with an approximate doubling of mortality and HF hospitalization compared to those with T2D or HF alone. [2] [3] [4] [5] The Swedish HF registry has revealed a median survival of 3.5 years in patients with both HF and T2D, compared with 4.6 years in those with HF alone. 6 Thus prevention of HF in patients with T2D
is a top priority. The EMPA-REG OUTCOME V R 7 trial showed that empagliflozin, in patients with T2D and cardiovascular (CV) disease (CVD), reduced CV mortality by 38%, HF hospitalization by 35%, and the composite of CV mortality or HF hospitalization by 34%. These benefits appeared indistinguishable in those with and without a previous diagnosis of HF at the baseline study visit. 8 The purposes of this report are to investigate the effects of empagliflozin in patients across the spectrum of HF and HF risk. Specifically, we sought to (i) assess if the impact of empagliflozin upon HF hospitalization and CV mortality was influenced by the estimated underlying risk for HF in those without baseline HF; (ii) determine the effect of empagliflozin on CV mortality in those with or without baseline or incident HF during the trial; and (iii) further explore the apparent rapidity of empagliflozin's reduction in HF hospitalizations.
Methods

Study design
The design and primary study results of the EMPA-REG OUTCOME V R trial (NCT01131676) have been reported. [7] [8] [9] In brief, the population studied were patients with T2D (HbA1C 7-10% and eGFR >30 mL/min/ 1.73 m 2 ), with established atherosclerotic CVD; HF was neither required nor excluded as an eligibility criterion. Patients were randomized to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care. All CV outcome events, HF hospitalizations, and deaths were prospectively adjudicated by blinded clinical events committees. [7] [8] [9] Hospitalization for HF was defined as an event requiring an admission to an in-patient unit or a 12-h stay in the emergency department as a result of clinical manifestations of new or worsening HF. An additional criterion was the need for increased HF therapy that included (i) initiation or uptitration of diuretics, inotropes, or vasodilator therapy, and/or (ii) initiation of mechanical or surgical therapy, such as mechanical circulatory support, heart transplantation or ventricular pacing to improve cardiac function, or (iii) use of ultrafiltration, haemofiltration, or dialysis directed at the treatment of HF. Prevalent HF at baseline was assessed based on presence of conditions or diagnosis fulfilling narrow standardized MedDRA query (SMQ) 'cardiac failure' (see Supplementary material online, Table S1 ). This narrow SMQ was also used to define patients with investigator reported HF or HF events during the conduct of the trial in those patients who were not recorded as having HF at baseline.
Heart failure risk, heart failure burden, and the temporal trajectory of benefit
The 5-year risk for incident HF risk among the 89.9% of the trial cohort without baseline HF was assessed using the 9-variable Health ABC HF Risk score, 10 which incorporates age, coronary artery disease, systolic blood pressure, heart rate, left ventricular hypertrophy (assessed by electrocardiogram), smoking, serum albumin, fasting blood glucose, and creatinine. The score has previously been validated internally (in the Health ABC study) and externally (in the Cardiovascular Health Study). 10, 11 Risk was then classified as low-to-average (5-year HF occurrence <10%), high (10-20%), and very high (> _20%). Secondly, patients with investigator-reported HF at baseline, those with at least one adjudicated HF hospitalization during the trial, and those with investigator-reported incident HF (but without a corresponding HF hospitalization) during the trial were grouped and defined as patients with 'HF burden'. This allowed us to assess the impact of empagliflozin on CV and HF mortality on the totality of those with (vs. without) either baseline or incident HF. We postulated that the treatment effect of empagliflozin on CV mortality would be consistent irrespective of HF burden. Third, we explored the time-trajectories for the reduction in HF hospitalization in a time-to-benefit analysis to further explore the apparent rapidity of the effect on this outcome.
Statistical analysis
Based on the previously reported consistency of effect, 7 analyses were performed on the pooled empagliflozin dose groups vs. placebo. For the analysis of outcomes in relation to baseline HF risk, a time-to-first-event approach, utilizing a Cox proportional hazards model with factors for age, sex, baseline HbA1c, baseline eGFR, baseline body mass index, region, baseline HF risk score, study treatment assignment, and the interaction of the baseline Health ABC HF Risk score and study treatment assignment. Cumulative incidence function estimates were corrected for non-CV mortality as a competing risk. 12 Due to the declining numbers of patients at risk, cumulative incidence plots were truncated at 48 months.
To analyse effects on CV death by HF burden, we assessed treatment group differences in CV mortality in subgroups of patients who satisfied the following criteria: (i) experiencing at least one hospitalization for HF following randomization (adjudicated), (ii) experiencing HF identified by the investigator as an adverse event (HF AE ) per narrow SMQ (see Supplementary material online, Table S1 ) following randomization (irrespective of HF status at baseline and not necessarily involving hospitalization), and (iii) having HF at baseline or experiencing a hospitalization for HF or HF AE following randomization. Time to CV death derived from randomization (for patients with HF BL ) and from date of first HF episode for patients with HHF or HF AE. As a sensitivity analysis to this approach we also included, in patients with/without HF at baseline, incident HF events as time-dependent covariates to assess if the occurrence of HF during the study could explain between-group (i.e. pooled empagliflozin vs. placebo) differences observed. Further, we modelled incident HF events as time-dependent covariates with an interaction with treatment to see if the treatment difference in CV death over time was consistent in patients with/without HF at baseline and during the study.
Time trajectories for effects on HF hospitalizations were expressed by cumulative probabilities and derived as hazard ratios (HRs) and 95% confidence intervals (CIs). Hazard ratios were also provided sequentially for specified time-points (i.e. Day 360, Day 540, Day 720, Day 900, Day 1080, and Day 1260) following randomization.
All analyses were conducted following a modified intent-to-treat approach in patients treated with at least one dose of study drug. Each patient who did not have an event was censored on the last day they were known to be free of the outcome. All analyses were performed on a nominal two-sided a = 0.05 without adjustment for multiplicity. Statistical analyses were performed using SAS V R version 9. 
Results
Study population
Overall study population characteristics have been described previously. In patients without HF at baseline (89.9%), the median Health ABC score was 4 (range, -8 to 16) in the placebo group and 4 (-8 to 18) in the pooled empagliflozin group. The distribution across the spectrum of HF risk was balanced across treatment arms (see Supplementary material online, Figure S1 ). Overall 67.2% of the population were at low-to-average, 24.2% at high, and 5.1% at very-high 5-year risk. Men had a slightly higher Health ABC risk score than women (see Supplementary material online, Figure S2 ). Patients in the highest risk category were older, had more comorbidities, and were exposed to more polypharmacy than those in the lower risk categories. The highest risk group also had a worse cardiometabolic profile ( Table 1 , Supplementary material online, Table S2 ).
Heart failure outcomes stratified by heart failure risk Figure 1A-C) , as well as the individual components ( Figure 1D) . A separation of the cumulative incidence curves appeared early and the reduction of risk persisted for the duration of the trial ( Figure 1A-C) . (Table 2) , although the absolute risk reduction was lower (1.5%), due to their overall lower CV risk profile. The total number of deaths in the baseline or incident HF population comprised 37.9% of the overall CV deaths, whereas 62.1% stemmed from the population without any HF burden ( Table  2) . As indicated in Supplementary material online, Figure S3 , the CV mortality reduction with empagliflozin in the patients with HF burden (baseline or incident HF) was observed early.
A sensitivity analysis comprised all patients, kept the randomization principle (i.e. subpopulation were not chosen based on data post-randomization), and included HF burden as a time-dependent co-variate. In this analysis, the overall time to CV death HR remained consistent . Furthermore, when we modelled HF burden as a time-dependent covariate with an interaction with treatment we found that the interaction P-value was >0.05 for all three types of HF-burden definitions we used. Time to CV death derived from randomization (for patients with HF BL ) and from date of first HF episode for patients with HHF or HF AE . HR, hazard ratio; CI, confidence intervals; HF, heart failure; HF BL , heart failure at baseline; HHF, hospitalization for heart failure, HF AE , heart failure reported as an adverse event by the investigator, according to preferred terms of narrow SMQ 'cardiac failure '. a Hazard ratio and confidence intervals determined from Cox proportional hazards model.
Effects of empagliflozin on risk for cardiovascular death and heart failure . 
Time trajectory of benefit for heart failure hospitalization
Reductions in the risk for HF hospitalization with empagliflozin vs. placebo were observed by the first month and persisted for the duration of the trial (Figure 2A) . The HR stabilized as the number of patients with events increased over time ( Figure 2B ).
Discussion
We have previously reported that empagliflozin reduces both CV mortality in patients with a prior history of HF, and with nonadjudicated outcomes such as investigator reported HF and in patients prescribed loop diuretics. 7, 8 In the present analysis, we have extended the analysis using a validated HF risk score to determine the benefit of empagliflozin on HF admission and CV mortality in patients with a wide range of baseline characteristics and CV risk, including those with lower a priori HF risk. The present analyses confirm that empagliflozin has an important and robust treatment effect, reducing CV mortality and HF hospitalizations in patients at both high and lower risk, based on the validated Health ABC HF risk score, 10, 11 and in patients with or without either baseline and incident HF. These analyses therefore further underpin the recent ESC HF guideline, 13 suggesting that empagliflozin should be considered in patients with T2D in order to prevent or delay the onset of HF and prolong Measures of cardiac function, or biomarkers like NT-proBNP, were not available in EMPA-REG OUTCOME V R . However, a substantial proportion of its participants without a diagnosis of HF at baseline likely had left ventricular dysfunction (either diastolic or systolic), since they were older, had a long history of T2D, and had widely prevalent coronary artery disease and hypertension. In support of this contention, the Health ABC HF risk score, which also is proven to identify patients at risk for HF in the absence of availability of cardiac biomarkers, 15 identified almost 30% of the study's treatment population as having a high (24.2%) or a very high risk (5.1%) of developing clinical HF. Notably, the very high-risk patients in the placebo group of the study had a risk of being hospitalized for HF (3.33/ 100 years risk) and CV mortality (4.72/100 years risk). This is actually not dissimilar to the corresponding event rates in those who already had HF at the baseline study visit (HF hospitalization 5.24/100 years risk, CV mortality 4.26/100 years risk). These data suggest that an important proportion of EMPA-REG OUTCOME V R patients might actually have had HF that was not fully evident clinically or at least some degree of left ventricular dysfunction. It also underscores the importance of identifying susceptible individuals to optimize preventive strategies.
Other studies have also suggested that there is a sizable proportion of T2D patients with unrecognized HF, 16, 17 with up to 40% with asymptomatic left ventricular diastolic dysfunction. 18 Indeed, the ACC/AHA classification of Stage A HF recognizes that diabetes is one of the comorbidities associated with a high risk of developing HF. 19 Patients with HF burden in EMPA-REG OUTCOME-i.e. those with either baseline or incident HF-comprised 13.6% of the total patient cohort. These subjects had a substantially increased CV mortality (15.3% in the placebo arm) compared with individuals with no HF burden (4.2% in the placebo arm). As a consequence of this high risk, more than one-third of the CV deaths in the study occurred in the HF burden population, where also the largest absolute risk reduction in CV death from empagliflozin was observed (4.9% vs. 1.5% ). Yet, empagliflozin had a similar relative CV mortality benefit in patients with [HR 0.67 (0.47-0.97)] and without HF burden [HR 0.63 (0.48-0.84)]. These findings of the EMPA REG OUTCOME V R trial, alongside the evidence of beneficial effects in the low HF risk population, substantiate the benefits of empagliflozin across the spectrum of HF risk.
The rapid effect of empagliflozin on HF outcomes is striking. The reason for this early effect is not fully understood, as the trial was not designed to determine the mechanisms for the CVD benefits. A similar rapid effect on HF hospitalization was recently reported with another SGLT2 inhibitor, canagliflozin, in the CANVAS-program. 20 It is possible that some of the HF benefits are consequent to improved haemodynamics with a reduction of loading of the myocardium. [21] [22] [23] In conclusion, the current analyses show that the SGLT2 inhibitor empagliflozin reduces adverse HF outcomes across the spectrum of HF risk. Rapid and robust benefits were observed in those with baseline/incident HF vs. those with no HF burden as well as in those at low and high risk for HF.
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